Alan Lawrenson posted an interesting reply to a recent posting on "Cracking neck pain" in which he referenced clinical trials in Australia of a new treatment. I looked that treatment up and found this article:
ncbi.nlm.nih.gov/pmc/articl...
My inexpert reading of that article led me to the following conclusions:
1. The treatment
About 80% of men with prostate cancer have great overexpression of an antigen named "prostate‐specific membrane antigen" (PSMA) on their tumor cells. ("Overexpression" means that the tumor cells are producing a lot more of these antigen molecules than normal cells.) PSMA is a molecule that appears on the surface of tumor cells that can be "recognized" by an antibody that will bind to it. (An "antibody" is a kind of molecule that latches on to another molecule, an "antigen" like PSMA, and leaves other molecules alone.) Lutetium-177 is a radioactive isotope of the element Lutetium that can be manufactured and bound to an antibody for PSMA. A solution containing this compound is injected into the patient. The molecules of antibody + Lu-177 bind to the PSMA on the surface of cancer cells, and the radiation kills them. Apparently, very few other cells are damaged by the treatment.
Unlike Xofigo, this "targeted therapy" attacks cancer in soft tissue, not just in bones. So if you've got metastases, for example, in the liver, lungs, stomach, etc., they can be treated by this therapy.
2. Results.
Not everyone with PCa has lots of PSMA. Those who don't won't benefit. However 80% is a pretty good percentage who do.
Side effects look to be pretty mild. It looks like most men tolerate this treatment very well.
I don't see any evidence that this is a cure even for those who do have lots of PSMA. Like all of the other treatments, it appears that cancer adapts and eventually there will be tumor cells that don't express PSMA and are not killed by the treatment.
Also like all of the other treatments, some men will benefit a whole lot, others only a little, and others not at all. However, this treatment is unlike chemo, ADT, or immunotherapies and it looks to me like failing all of the other treatments does not mean you'll fail this one. I think that's what we need - new treatment types that work when the others have stopped working.
3. How do you get it?
It's currently only available in clinical trials. Those of us who are ready to try clinical trials might look for it.
Alan